Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Can

Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT06704620 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 430 participants, started 2024-12 and due to reach its primary completion in 2026-11. Interventions recorded: Diphenhydramine; Tislelizumab; Pemetrexed; Albumin paclitaxel; Carboplatin; Cisplatin. Conditions listed: Advanced and Metastatic NSCLC. Primary outcome: PFS. Lung eligibility wording from the registry: "Patients diagnosed with stage IIIB-IV NSCLC by imaging, tissue and/or cytology (according to AJCC 9th edition), or primary stage IIIB-IV NSCLC that relapses after surgery (if adjuvant therapy has been used, the drug must be discontinued for more than 6 months);Patients with IIIB/C are unable to unde". Sites: China. No results are recorded here; the registry entry is the source.